Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Healthtrust
McKinsey
Cipla
US Department of Justice
Farmers Insurance
AstraZeneca
Daiichi Sankyo
Teva

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203106

« Back to Dashboard

NDA 203106 describes KLOR-CON, which is a drug marketed by Upsher-smith Labs and is included in four NDAs. It is available from seventeen suppliers. Additional details are available on the KLOR-CON profile page.

The generic ingredient in KLOR-CON is potassium chloride. There are two hundred and thirty-four drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
Summary for 203106
Tradename:KLOR-CON
Applicant:Upsher-smith Labs
Ingredient:potassium chloride
Patents:0
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 203106
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KLOR-CON potassium chloride CAPSULE, EXTENDED RELEASE;ORAL 203106 ANDA Upsher-Smith Laboratories, LLC 0245-0101 N 0245-0101-00
KLOR-CON potassium chloride CAPSULE, EXTENDED RELEASE;ORAL 203106 ANDA Upsher-Smith Laboratories, LLC 0245-0101 N 0245-0101-50

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength8MEQ
Approval Date:Jul 10, 2015TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Jul 10, 2015TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Deloitte
US Army
Merck
Mallinckrodt
Boehringer Ingelheim
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot